Poxel - Assemblée Générale des actionnaires du 9 mai 2019
Proxinvest attire l'attention sur les lacunes relatives à la rémunération des mandataires sociaux. D'une part, un grand effort dans la communication des montants et des critères doit être fait de la part de la Société. L'année dernière cette remarque avait été faite, mais la Société ne semble pas avoir pris en compte nos recommandations.
Par ailleurs, l'absence de plafond pour les dirgeants dans les résolutions 24, 25 et 26 et l'absence de conditions de performance est vraiment regrettable, ce qui conduit à des montants attribuables potentiellement très élevés aux seuls dirigeants. Nous avons recommandé l'opposition.
Enfin, une dernière remarque peut être faite sur la confusion que semble faire la Société. Le Président du Conseil n'est pas un mandataire social exécutif, mais un mandataire social non-exécutif. Il ne participe pas à la stratégie opérationnelle de la société et de ce fait, il n'est pas concevable qu'il puisse toucher une rémunération variable.
Poxel is a clinical-stage biopharmaceutical company focused on the development of treatments for type 2 diabetes and metabolic disease. Co.'s two drug candidates, Imeglimin and PXL770, are intended to complement and augment existing type 2 diabetes therapies, including in patients who no longer fully respond to such therapies, with the goal of helping patients better control their type 2 diabetes and reduce potentially disabling or fatal complications.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.